Companies Outperforming the FANG+ Index Under President Donald Trump - Seite 3

BeiGene Ltd. (NASDAQ:BGNE) shares are up over 90% since the inception of the FANG+. Founded in 2010, this giant in China's emerging biopharma industry develops innovative cancer treatments has capitalized on its access to China's vast population of cancer patients and strategic partnerships with multi-billion-dollar Merck and Celgene. The company's broad portfolio includes a drug in late-stage clinical trials for the treatment of Hodgkin's lymphoma and non-small cell lung cancer. In August, BeiGene raised $903 million through a secondary listing in Hong Kong's stock exchange. China is making a massive push to grow its bioeconomy: biopharma, agricultural biotech, and industrial biotech, among other fledgling markets. At the end of March, the company announced it had enrolled more than 2,300 patients in over 30 clinical trials worldwide.

In July, BeiGene announced clinical and regulatory updates for three separate late-stage drug candidates. First, it told investors it planned to pursue accelerated approval of Zanubrutinib as a treatment for Waldenstrom macroglobulinemia, a type of non-Hodgkin lymphoma, in the United States. It's currently enrolled in a global phase 3 trial and has already received fast-track designation from the U.S. Food and Drug Administration.

DISCLAIMER: Financialnewsmedia.com (FNM) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM has been compensated nineteen hundred dollars for news coverage of the current press release issued by Generation Next Franchise Brands Inc. by the company. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.